Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018

  • ID: 4539033
  • Clinical Trials
  • Region: Global
  • 277 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Allergan Plc
  • Bristol-Myers Squibb Co
  • Galmed International Ltd
  • Genextra Spa
  • Genfit SA
  • Gilead Sciences Inc
  • MORE
Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018

Summary

The clinical trial report, “Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018" provides an overview of Non-Alcoholic Steatohepatitis (NASH) clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The Clinical Trial Reports are generated using the author's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan Plc
  • Bristol-Myers Squibb Co
  • Galmed International Ltd
  • Genextra Spa
  • Genfit SA
  • Gilead Sciences Inc
  • MORE
  • Report Guidance
  • Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Non-Alcoholic Steatohepatitis (NASH)
  • Apr 09, 2018: Second Genome Presents Clinical and Preclinical Data Supporting Development of Its P2X7 Inhibitor, SGM-1019, in NASH at the EASL International Liver Congress 2018
  • Apr 09, 2018: Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical Studies at the 2018 International Liver Congress of the European Association for the Study of the Liver (EASL)
  • Apr 05, 2018: Promethera Biosciences to Present New NASH Data at Two International Scientific and Partnering Conferences in April
  • Apr 04, 2018: Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018
  • Apr 04, 2018: Conatus Pharmaceuticals Announces Top-line Results from Phase 2b POLT-HCV-SVR Clinical Trial
  • Apr 01, 2018: MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis
  • Mar 28, 2018: GENFIT: Presentations at EASL 2018 Annual Congress Highlight Progress in NASH Diagnostics, Combination Therapies and Deep-learning Applications in Medical Imaging
  • Mar 28, 2018: Enanta Pharmaceuticals Announces Poster Presentations on EDP-305 at ICL 2018
  • Mar 28, 2018: Lanifibranor carcinogenicity studies: Progressing as planned and interim results in rats indicate no compound related urinary bladder tumors
  • Mar 27, 2018: Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASL
  • Mar 23, 2018: Intercept Announces Multiple New Ocaliva (obeticholic acid) Data Presentations at the International Liver Congress 2018
  • Mar 14, 2018: Can-Fite to Present at the NASH 2nd Annual H.C. Wainwright Investor Conference
  • Mar 12, 2018: NGM Bio Announces Publication In The Lancet Of Phase 2 Study Of NGM282 In NASH Patients And Upcoming Presentations Of NGM282 NASH Histology Data And NGM282 PSC Data At The International Liver Congress 2018
  • Mar 12, 2018: Immuron Commences US Non-Deal Institutional Investor Roadshow
  • Mar 08, 2018: Immuron Reports Positive Results in NASH Clinical Trial
  • Mar 08, 2018: Galectin Therapeutics to Present at 2nd Annual H.C. Wainwright NASH Investor Conference
  • Mar 08, 2018: Gastrointestinal Hormone Measurably Improved Symptoms of Non-Alcoholic Fatty Liver Disease
  • Mar 07, 2018: Gencia Will Present Preclinical Results in the DIAMOND Mice Supporting the Therapeutic Potential of Its Lead Mitochondrial Therapeutic, GEN-3026, to Treat NASH at the International Liver Congress
  • Mar 07, 2018: Cerenis Therapeutics Announces Approval to launch the Phase I Study of repeated and increasing doses to assess CER-209 in NASH/NAFLD
  • Mar 06, 2018: Can-Fite to Provide Update on Liver Drug Namodenoson at the 30th Annual ROTH Conference
  • Mar 05, 2018: Conatus Pharmaceuticals to Highlight Anticipated Clinical Data Readouts at Upcoming Investor Conferences
  • Mar 05, 2018: Second Genome Appoints Matthew W. McClure, M.D., as Chief Medical Officer
  • Feb 28, 2018: Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson
  • Feb 22, 2018: Can Fite Announces the Submission of Safety Reports for Namodenoson to FDA and other Regulatory Authorities
  • Feb 14, 2018: Galmed Announces ARRIVE Study Data
  • Feb 12, 2018: Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson
  • Feb 12, 2018: Intercept Announces Phase 3 REVERSE Trial Evaluating OCA for the Treatment of NASH Patients with Compensated Cirrhosis
  • Feb 05, 2018: NGM Reports Top-Line Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis (PSC)
  • Jan 30, 2018: Madrigal Announces Acceptance of MGL-3196 Abstract for a Main Plenary Presentation at The International Liver Congress 2018
  • Jan 28, 2018: MediciNova Announces MN-001 (tipelukast) NASH/NAFLD Phase 2 Trial Interim Results Selected for Presentation at the International Liver Congress 2018 in Paris, France
  • Jan 23, 2018: GENFIT: Official Launch of the NASH Pediatric Program, following PIP and PSP Agreement by EMA and FDA
  • Clinical Trial Profile Snapshots
  • Appendix
  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About
  • Contact
  • Source
List of Tables
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Region, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, North America, Top Countries, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018*
  • Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, G7 Countries (%), 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
  • Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, E7 Countries (%), 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Phase, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Phase 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Trial Status, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, by End Point Status, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
List of Figures
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Region (%), 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, North America, Top Countries (%), 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018*
  • Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, G7 Countries (%), 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
  • Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, E7 Countries (%), 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Phase (%), 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Trial Status, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, by End Point Status, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
  • Methodology
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Gilead Sciences Inc
  • Pfizer Inc
  • Novartis AG
  • Allergan Plc
  • Conatus Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Genextra Spa
  • WCCT Global Inc
  • Genfit SA
  • Galmed International Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll